Emmaus Life Sciences (NASDAQ:EMMA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. The firm presently has a $2.25 price target on the stock. Zacks Investment Research‘s price objective suggests a potential upside of 12.50% from the company’s current price.
According to Zacks, “Emmaus Life Sciences Inc. is a commercial-stage biopharmaceutical company. It is engaged in the discovery, development, marketing and sale of treatments and therapies, for rare and orphan disease categories. Emmaus Life Sciences Inc., formerly known MYnd Analytics Inc., is based in Torrance, United States. “
Separately, Dawson James cut shares of Emmaus Life Sciences from a “buy” rating to a “neutral” rating in a report on Tuesday, September 24th.
Emmaus Life Sciences (NASDAQ:EMMA) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.20) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.20) by $1.00. Emmaus Life Sciences had a negative net margin of 489.28% and a negative return on equity of 511.05%. The business had revenue of $0.53 million for the quarter, compared to analyst estimates of $0.57 million. As a group, sell-side analysts predict that Emmaus Life Sciences will post -5.57 EPS for the current fiscal year.
In other Emmaus Life Sciences news, Director Wei Peu Zen bought 40,000 shares of Emmaus Life Sciences stock in a transaction that occurred on Monday, September 9th. The stock was purchased at an average cost of $4.25 per share, for a total transaction of $170,000.00. Also, Chairman Yutaka Niihara bought 19,500 shares of Emmaus Life Sciences stock in a transaction that occurred on Wednesday, August 21st. The shares were acquired at an average price of $3.38 per share, with a total value of $65,910.00. The disclosure for this purchase can be found here. Insiders have purchased 212,989 shares of company stock valued at $814,898 over the last 90 days. 36.88% of the stock is currently owned by insiders.
Emmaus Life Sciences Company Profile
Emmaus Life Sciences, Inc engages in the discovery, development, and commercialization of treatments and therapies primarily for rare and orphan diseases in the United States and internationally. It provides Endari, which is L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older; NutreStore L-glutamine powder; and AminoPure, a nutritional supplement.
Recommended Story: Discover Your Risk Tolerance
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Emmaus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emmaus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.